Kommersiellt obunden läkemedelsinformation riktad till läkare och sjukvårdspersonal

Kabergolin

Klassificering: A

Preparat: Cabaser®, Cabergoline 2care4, Cabergoline Hexal, Cabergoline Sandoz, Cabergoline Teva, Dostinex, Dostinex®

ATC kod: G02CB03, N04BC06

Substanser: kabergolin

Sammanfattning

Kabergolin används som andrahandsbehandling till patienter med Parkinsons sjukdom, för att hämma laktation, vid hyperlaktation samt vid hyperprolaktinom. Studier har visat att kvinnor och män svarar lika bra på behandling med kabergolin vid hyperprolaktinemi. Inga signifikanta könsskillnader har observerats för sannolikheten att få normala prolaktin-nivåer.
 
Kunskapsunderlaget avseende skillnader mellan kvinnor och män är begränsat och motiverar inte olika dosering eller behandling.

Additional information

Pharmacokinetics and dosing

No studies with a clinically relevant sex analysis regarding the pharmacokinetics or dosing of cabergoline have been found .

Effects

A clinical trial studying sex differences in presentation and response to cabergoline therapy in patients with newly diagnosed hyperprolactinemia, found that successful response to carbergoline treatment for 6 months was similar in women and men. Prolactin levels normalized more frequently in micro- than in macroadenoma patients (86% vs. 64%), without a sex difference (70% vs. 69%, p=0.9). The sizes of macro- and microprolactinomas were reduced by 38 ±29% to 52 ±24%, and there was no difference in the amount of tumor shrinkage between men and women [1]. In another clinical study of carbergoline treatment in patients with hyperprolactinemia, men had less likelihood of achieving normal prolactin levels than women (75% vs. 90%). However, considered that the large majority of men had a macroprolactinoma (86% vs. 38% for women), which correlates with higher prolactin levels, sex had no independent influence on success rates. When only microprolactinomas were considered, the outcome was similar in men and women (92% vs. 93%) [2].

Adverse effects

Another clinical trial found no significant differences in prevalence of tricuspid regurgitation at any valve between hyperprolatinaemic men and women receiving carbergoline [3].

Reproductive health issues

Regarding teratogenic aspects, please consult the Drugs and Birth Defects Database (in Swedish, Janusmed fosterpåverkan).

Försäljning på recept

Något fler kvinnor än män hämtade ut tabletter innehållande kabergolin (ATC-kod N04BC06) på recept i Sverige år 2015, totalt 379 kvinnor och 316 män.,,Fler kvinnor än män hämtade ut tabletter innehållande kabergolin (ATC-kod G02CB03) på recept i Sverige år 2015, totalt 955 kvinnor och 376 män [4].

Uppdaterat: 2019-02-26

Litteratursökningsdatum: 2013-04-04

Referenser

  1. Colao A, Sarno AD, Cappabianca P, Briganti F, Pivonello R, Somma CD et al. Gender differences in the prevalence, clinical features and response to cabergoline in hyperprolactinemia. Eur J Endocrinol. 2003;148:325-31. PubMed
  2. Verhelst J, Abs R, Maiter D, van den Bruel A, Vandeweghe M, Velkeniers B et al. Cabergoline in the treatment of hyperprolactinemia: a study in 455 patients. J Clin Endocrinol Metab. 1999;84:2518-22. PubMed
  3. Nachtigall LB, Valassi E, Lo J, McCarty D, Passeri J, Biller BM et al. Gender effects on cardiac valvular function in hyperprolactinaemic patients receiving cabergoline: a retrospective study. Clin Endocrinol (Oxf). 2010;72:53-8. PubMed
  4. Läkemedelsstatistik. Stockholm: Socialstyrelsen. 2015 [cited 2016-04-05.] länk

Författare: Linnéa Karlsson Lind, Desirée Loikas

Faktagranskat av: Expertrådet för neurologiska sjukdomar

Godkänt av: Mia von Euler